Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kythera Biopharmaceuticals
No study medication is administered in this study.
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
1. Any participant who completed follow-up visits at 12 and 24 weeks after the last dose in one of the two predecessor studies
2. Willingness to comply with the schedule and procedures of this study.
3. Signed informed consent form (ICF).
You may not be if
1\. Participants who have had any treatment or condition (e.g., pregnancy or metabolic disease, which may lead to unstable weight) that may affect assessment of safety or efficacy since enrollment in the predecessor study.
Clareo Health | Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
